Literature DB >> 27456484

Critical Role of IL-22/IL22-RA1 Signaling in Pneumococcal Pneumonia.

Giraldina Trevejo-Nunez1, Waleed Elsegeiny1, Parker Conboy1, Kong Chen1, Jay K Kolls2.   

Abstract

IL-22-IL-22R signaling plays a crucial role in regulating host defenses against extracellular pathogens, particularly in the intestine, through the induction of antimicrobial peptides and chemotactic genes. However, the role of IL-22-IL-22R is understudied in Streptococcus pneumoniae lung infection, a prevalent pathogen of pneumonia. This paper presents the findings of IL-22 signaling during a murine model of pneumococcal pneumonia and improvement of bacterial burden upon IL-22 administration. IL-22 was rapidly induced in the lung during pneumococcal infection in wild-type mice, and Il22(-/-) mice had higher pneumococcal burdens compared with controls. Additionally, mice with hepatic-specific deletion of Il22ra1 also had higher bacterial burdens in lungs compared with littermate controls after intrapulmonary pneumococcal infection, suggesting that IL-22 signaling in the liver is important to control pneumococcal pneumonia. Thus, we hypothesized that enhancement of IL-22 signaling would control pneumococcal burden in lung tissues in an experimental pneumonia model. Administration of rIL-22 systemically to infected wild-type mice decreased bacterial burden in lung and liver at 24 h postinfection. Our in vitro studies also showed that mice treated with IL-22 had increased C3 expression in the liver compared with the isotype control group. Furthermore, serum from mice treated with IL-22 had improved opsonic capacity by increasing C3 binding on S. pneumoniae Taken together, endogenous IL-22 and hepatic IL-22R signaling play critical roles in controlling pneumococcal lung burden, and systemic IL-22 decreases bacterial burden in the lungs and peripheral organs by potentiating C3 opsonization on bacterial surfaces, through the increase of hepatic C3 expression.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27456484      PMCID: PMC4992592          DOI: 10.4049/jimmunol.1600528

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  IL-22 induces an acute-phase response.

Authors:  Spencer C Liang; Cheryl Nickerson-Nutter; Debra D Pittman; Yijun Carrier; Debra G Goodwin; Kathleen M Shields; Andre-Jean Lambert; Scott H Schelling; Quintus G Medley; Hak-Ling Ma; Mary Collins; Kyriaki Dunussi-Joannopoulos; Lynette A Fouser
Journal:  J Immunol       Date:  2010-09-24       Impact factor: 5.422

2.  Adaptation of innate lymphoid cells to a micronutrient deficiency promotes type 2 barrier immunity.

Authors:  S P Spencer; C Wilhelm; Q Yang; J A Hall; N Bouladoux; A Boyd; T B Nutman; J F Urban; J Wang; T R Ramalingam; A Bhandoola; T A Wynn; Y Belkaid
Journal:  Science       Date:  2014-01-24       Impact factor: 47.728

3.  Elevated C-reactive protein and spontaneous bacterial peritonitis in children with chronic liver disease and ascites.

Authors:  Marcela Preto-Zamperlini; Sylvia Costa Lima Farhat; Maria Beatriz Moliterno Perondi; Adriana Pozzi Pestana; Patricia Salles Cunha; Renata Pereira Sustovich Pugliese; Cláudio Schvartsman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2014-01       Impact factor: 2.839

4.  Therapeutic Role of Interleukin 22 in Experimental Intra-abdominal Klebsiella pneumoniae Infection in Mice.

Authors:  Mingquan Zheng; William Horne; Jeremy P McAleer; Derek Pociask; Taylor Eddens; Misty Good; Bin Gao; Jay K Kolls
Journal:  Infect Immun       Date:  2016-01-04       Impact factor: 3.441

5.  Hepatocyte-specific mutation of both NF-κB RelA and STAT3 abrogates the acute phase response in mice.

Authors:  Lee J Quinton; Matthew T Blahna; Matthew R Jones; Eri Allen; Joseph D Ferrari; Kristie L Hilliard; Xiaoling Zhang; Vishakha Sabharwal; Hana Algül; Shizuo Akira; Roland M Schmid; Stephen I Pelton; Avrum Spira; Joseph P Mizgerd
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

Review 6.  Interleukin-22: immunobiology and pathology.

Authors:  Jarrod A Dudakov; Alan M Hanash; Marcel R M van den Brink
Journal:  Annu Rev Immunol       Date:  2015-02-11       Impact factor: 28.527

7.  Morphine inhibits murine dendritic cell IL-23 production by modulating Toll-like receptor 2 and Nod2 signaling.

Authors:  Jinghua Wang; Jing Ma; Rick Charboneau; Roderick Barke; Sabita Roy
Journal:  J Biol Chem       Date:  2011-01-18       Impact factor: 5.157

8.  IL-22 is essential for lung epithelial repair following influenza infection.

Authors:  Derek A Pociask; Erich V Scheller; Sivanarayana Mandalapu; Kevin J McHugh; Richard I Enelow; Cheryl L Fattman; Jay K Kolls; John F Alcorn
Journal:  Am J Pathol       Date:  2013-03-11       Impact factor: 4.307

9.  Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10.

Authors:  Diane Lejeune; Laure Dumoutier; Stefan Constantinescu; Wiebe Kruijer; Jan Jacob Schuringa; Jean-Christophe Renauld
Journal:  J Biol Chem       Date:  2002-06-26       Impact factor: 5.157

10.  IL-22 increases the innate immunity of tissues.

Authors:  Kerstin Wolk; Stefanie Kunz; Ellen Witte; Markus Friedrich; Khusru Asadullah; Robert Sabat
Journal:  Immunity       Date:  2004-08       Impact factor: 31.745

View more
  26 in total

1.  Effects of Lactobacillus reuteri LR1 on the growth performance, intestinal morphology, and intestinal barrier function in weaned pigs.

Authors:  Hongbo Yi; Li Wang; Yunxia Xiong; Xiaolu Wen; Zhilin Wang; Xuefen Yang; Kaiguo Gao; Zongyong Jiang
Journal:  J Anim Sci       Date:  2018-06-04       Impact factor: 3.159

2.  Oral epithelial IL-22/STAT3 signaling licenses IL-17-mediated immunity to oral mucosal candidiasis.

Authors:  Felix E Y Aggor; Timothy J Break; Giraldina Trevejo-Nuñez; Natasha Whibley; Bianca M Coleman; Rachel D Bailey; Daniel H Kaplan; Julian R Naglik; Wei Shan; Amol C Shetty; Carrie McCracken; Scott K Durum; Partha S Biswas; Vincent M Bruno; Jay K Kolls; Michail S Lionakis; Sarah L Gaffen
Journal:  Sci Immunol       Date:  2020-06-05

3.  Interleukin-22 (IL-22) Binding Protein Constrains IL-22 Activity, Host Defense, and Oxidative Phosphorylation Genes during Pneumococcal Pneumonia.

Authors:  Giraldina Trevejo-Nunez; Waleed Elsegeiny; Felix E Y Aggor; Jamie L Tweedle; Zoe Kaplan; Pranali Gandhi; Patricia Castillo; Annabel Ferguson; John F Alcorn; Kong Chen; Jay K Kolls; Sarah L Gaffen
Journal:  Infect Immun       Date:  2019-10-18       Impact factor: 3.441

4.  Interleukin-22 Immunotherapy during Severe Influenza Enhances Lung Tissue Integrity and Reduces Secondary Bacterial Systemic Invasion.

Authors:  Ronan Le Goffic; François Trottein; Adeline Barthelemy; Valentin Sencio; Daphnée Soulard; Lucie Deruyter; Christelle Faveeuw
Journal:  Infect Immun       Date:  2018-06-21       Impact factor: 3.441

Review 5.  Integrative Physiology of Pneumonia.

Authors:  Lee J Quinton; Allan J Walkey; Joseph P Mizgerd
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

6.  The Effects of IFN-λ on Epithelial Barrier Function Contribute to Klebsiella pneumoniae ST258 Pneumonia.

Authors:  Danielle Ahn; Matthew Wickersham; Sebastian Riquelme; Alice Prince
Journal:  Am J Respir Cell Mol Biol       Date:  2019-02       Impact factor: 6.914

7.  Host immunology and rational immunotherapy for carbapenem-resistant Klebsiella pneumoniae infection.

Authors:  Naoki Iwanaga; Ivy Sandquist; Alanna Wanek; Janet McCombs; Kejing Song; Jay K Kolls
Journal:  JCI Insight       Date:  2020-04-23

8.  T-helper 22 cells develop as a distinct lineage from Th17 cells during bacterial infection and phenotypic stability is regulated by T-bet.

Authors:  Jessica L Barnes; Maximilian W Plank; Kelly Asquith; Steven Maltby; Lorena R Sabino; Gerard E Kaiko; Alyssa Lochrin; Jay C Horvat; Jemma R Mayall; Richard Y Kim; Philip M Hansbro; Simon Keely; Gabrielle T Belz; Hock L Tay; Paul S Foster
Journal:  Mucosal Immunol       Date:  2021-06-03       Impact factor: 7.313

9.  Interleukin 22 mitigates endothelial glycocalyx shedding after lipopolysaccharide injury.

Authors:  Sharven Taghavi; Sarah Abdullah; Juan Duchesne; Derek Pociask; Jay Kolls; Olan Jackson-Weaver
Journal:  J Trauma Acute Care Surg       Date:  2021-02-01       Impact factor: 3.697

Review 10.  The role of innate lymphoid cells in response to microbes at mucosal surfaces.

Authors:  Goo-Young Seo; Daniel A Giles; Mitchell Kronenberg
Journal:  Mucosal Immunol       Date:  2020-02-11       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.